Hancock Whitney Corp significantly reduced its stake in Agilent Technologies by 71.9% in the first quarter. According to new SEC filings, the fund sold 7,562 shares and now holds 2,951 shares of the medical research company.
Subscribe
Industry News
Stock Market
Agilent Technologies, Inc. $A Shares Sold by Hancock Whitney Corp
Photo by Markets Daily
Key Takeaways:
- Hancock Whitney Corp cut its stake in Agilent Technologies by 71.9%
- 7,562 shares were sold in the first quarter
- The fund now holds 2,951 shares of the medical research company
- The details were disclosed via an SEC filing
- The information was published by Markets Daily on 2025-09-08 08:58:56
Introduction to Hancock Whitney Corp’s Share Reduction
Hancock Whitney Corp has significantly reduced its holdings in Agilent Technologies, Inc., a medical research company listed on the New York Stock Exchange under the symbol A. According to the firm’s most recent filing with the Securities & Exchange Commission, the stake was cut by 71.9% in the first quarter.
Background on Agilent Technologies
Agilent Technologies specializes in the medical research sector. It operates on the NYSE under the ticker symbol A. While the details of the company’s broad portfolio are not included in this filing, the firm is widely recognized in its industry for scientific instrumentation and diagnostics.
Details from the SEC Filing
Recent disclosures indicate that Hancock Whitney Corp sold a total of 7,562 shares during the first quarter of the year. After this transaction, the fund retained 2,951 shares of Agilent Technologies. The filing highlights the significant scope of this change, signaling a major adjustment to Hancock Whitney Corp’s investment strategy.
Unknown Motives
Though the filing outlines the share sale and its scope, it does not elaborate on specific reasons fueling the move. No further indicators are provided regarding Hancock Whitney Corp’s outlook for Agilent Technologies or the broader research market.
Concluding Thoughts
This information, sourced from Hancock Whitney Corp’s disclosure to the SEC, underscores an intriguing recalibration of its portfolio. Published by Markets Daily on September 8, 2025, these details remain a key indicator of how institutional investors continually adjust their positions in leading companies within the medical research field.
